Thai PBS Thai PBS
Human trials of Thailand’s ChulaCov19 mRNA vaccine show promising results

Human trials of Thailand’s ChulaCov19 mRNA vaccine show promising results

23 Sept 05:15 Key points summarised by AI
  • Thailand's ChulaCov19 mRNA vaccine, developed by Chulalongkorn University, shows promising results in human trials, stimulating killer T-cells effective against Alpha, Delta, Beta, and Gamma COVID-19 variants.
  • Initial phase one trials in 36 volunteers (aged 18-55) demonstrated antibody production comparable to the Pfizer vaccine, with only mild to moderate, short-lived side effects.
  • Further trial phases are underway, with the project director anticipating public administration of a vaccine candidate before next year's Songkran festival, provided funding, manufacturing, and regulatory conditions are met.
Read full article
News 1/1
Skip > Skip >